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Transcatheter aortic valve replacement (TAVR) has trans-
formed the care of patients with aortic stenosis. The dissemi-
nation of this technology after its approval in the United States
in the wake of a pivotal randomized trial (1,2) has thus far
proceeded in a thoughtful and circumspect manner, guided by
a coalition of stakeholders dedicated to the delivery of high-
quality, patient-centered care. It is anticipated that a number
of transcatheter therapies for mitral regurgitation (MR) will
also become available for clinical use in selected patients. As an
example, the MitraClip device (Abbott Vascular, Santa Clara,
California) was approved October 24, 2013, for the reduction
of signiﬁcant (3þ), symptomatic, degenerative MR in highly
anatomically selected patients considered by an experienced
heart team to be at prohibitive risk for mitral valve surgery.
Other transcatheter approaches in development include mitral
annulus–based therapies, transapical neochordal implants,
valve-in-valve and valve-in-annuloplasty ring therapies, and
valve replacement therapies. A process similar to that adopted
for TAVR is proposed to ensure that such innovative treatments
are introduced into medical practice in the United States with
appropriate safeguards (3). The American College of Cardi-
ology (ACC), the American Association for Thoracic Surgery
(AATS), The Society of Thoracic Surgeons (STS), and the
Society of Cardiovascular Angiography and Interventions
(SCAI) Foundation have collaborated to write this overview to
set the stage for an ensuing series of documents, to be joined by
other professional societies, and to address the issues critical to
the appropriate integration of transcatheter MR therapies into
the care of selected patients with this disorder. In accordance
with the ACC’s policy on relationships with industry and other
entities (RWI), relevant author disclosures are included in
Appendix 1 of this document. In the spirit of full disclosure,
authors’ comprehensive RWI information, which includes
RWI not relevant to this document, is available online as a data
supplement to this document (http://jaccjacc.cardiosource.
com/acc_documents/2013_TTMR_Comprehensive_Author_
Disclosure_Table.pdf). RWI restrictions do not apply to
participation in the external peer review process for clinical
documents, in order to ensure that a variety of constituencies/
perspectives inform the ﬁnal paper. However, for purposes of
full disclosure, all relevant RWI for reviewers, as well as their
individual afﬁliations, are published in Appendix 2. Final
review and approval of the document was provided by the
respective boards of the 4 professional societies. These orga-
nizations are committed to providing guidance on key issues
having an impact on clinical care and believe this document
will help frame subsequent discussions regarding such tech-
nology as it continues to evolve.
1. Introduction
Catheter-based therapies for valvular heart disease, including
balloon valvuloplasty, have been in clinical use for over 3decades. More recently, transcatheter valve replacement tech-
nologies have dramatically altered the approach to children and
adults with congenital or post-surgical pulmonic valve disease
and to adults with degenerative aortic stenosis. Using the
lessons learned from the release of these transformational
technologies, this document seeks to highlight the critical issues
surrounding adult transcatheter MR therapies to properly align
the interests of all relevant stakeholders, including primary care
physicians; patients and their families; proceduralists (inter-
ventional cardiologists, cardiac surgeons); heart valve, heart
failure, and imaging experts; general and geriatric cardiologists;
other heart team members; and regulators, payers, professional
societies, and industry. In order to promote the expansion of this
technology to allow for best patient outcomes, new guidelines
and requirements for training, operator credentialing, and
institutional policies will be developed.
1.1. Key Questions
1. How will this technology be regulated and by what
authority?
2. Will the technology be available in all centers to all
interested parties, or will it be restricted to specialized
centers? If the latter, how will these centers be speci-
ﬁed? What constitutes a heart valve center of excel-
lence? Are the characteristics of a valve reference
center the same for aortic and mitral disease?
3. What training will be required for interventional
cardiologists and surgeons, and how will it be accom-
plished? Will the training be the same for cardiologists
and surgeons? What criteria will be utilized to grant
procedural privileges?
4. What clinical, procedural, administrative, and follow-
up data will be collected and by what mechanism to
ensure rigorous assessment of outcomes across centers
and provide a framework for comparative effectiveness
research and cost-effectiveness assessment? How will
patient cohorts that are most and least likely to beneﬁt
from this technology be identiﬁed?
5. What mechanisms will exist to allow for the careful
extension of this technology to the treatment of other
groups of patients not included or studied in the initial,
randomized clinical trials?
6. How will this technology be reimbursed? Will there be
a national coverage determination?
Answers to these questions are complex and inﬂuenced in
large measure by the number of interested stakeholders. Trans-
catheter treatment of MR is technically challenging and thus far
of limited scope. Maintaining the best interests of patients
constitutes the driving force behind any initiative of this type.
2. Mitral Valve Surgery
MR can result from abnormalities in the structure and/or
function of 1 or more of the 4 components of the mitral
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842apparatus (leaﬂets, annulus, chordae tendineae, and papillary
muscles/left ventricular [LV] myocardium). Primary MR
refers to abnormalities of the leaﬂets and is most commonly
due to myxomatous degeneration, especially in developed
countries. With secondary or functional MR, the leaﬂets are
usually normal, and the regurgitation occurs as a consequence
of adverse LV remodeling, with papillary muscle displace-
ment, leaﬂet tethering, and annular dilatation. The prevalence
of moderate to severe mitral valve disease (more often
regurgitant rather than stenotic) increases as a function of age
and exceeds that of aortic valve disease on both a community
and population level when assessed by echocardiography (4).
Prognosis with MR differs as a function of both etiology and
LV function; treatment protocols, including medical inter-
ventions and cardiac resynchronization therapy when indi-
cated, must be tailored to the underlying disease substrate.
The indications for and timing of surgery for treatment of
MR have evolved considerably over the past several decades
as both operative techniques and patient outcomes have
improved (5,6). These trends are especially true for patients
with severe, degenerative MR of a myxomatous nature for
whom valve repair has become the preferred strategy whenever
feasible. Isolated valve repair for this indication can now be
accomplished through a variety of minimally invasive
approaches, including with the use of robotic techniques in
highly specialized surgical centers. Patients are interested in
pursuing less invasive approaches in the hopes of reducing the
burden of perioperative complications and discomfort, without
compromising their chances for a successful and durable
outcome. Expert mitral valve surgeons may employ several
techniques to accomplish this task, including leaﬂet resection,
neochordal construction, prosthetic ring or band insertion, and
edge-to-edge leaﬂet approximation. Emerging transcatheter
technologies have attempted to replicate 1 or more of these
surgical principles, thus far with varying success in clinical and
experimental settings. Perioperativemortality rates for selected,
low-surgical-risk patients with severe degenerative MR are
now <1% in major referral centers where a successful repair
can be accomplished in over 95% of patients with isolated
posterior mitral leaﬂet pathology. Nevertheless, there remains
concern that patients with severe, degenerative MR are not
referred for surgical intervention in a timely fashion, even in
referral centers of excellence (7). On the other end of the
spectrum, symptomatic patients with functional MR that is due
either to adverse LV remodeling after myocardial infarction or
to a nonischemic cardiomyopathic process may beneﬁt from
surgical treatment to reduce or eliminate the excess LV volume
load. A down-sized annuloplasty repair or chordal-sparing
valve replacement is undertaken as dictated by the anatomic
and hemodynamic features encountered in an individual
patient. Many such patients are considered intermediate-to-
high risk for perioperative mortality or major complications.
A less invasive approach, in combination with percutaneous
coronary intervention for concomitant treatment of important
coronary artery disease, may be of value in this setting. The use
of transcatheter mitral valve repair in patients with functionalMR appears to be both feasible and beneﬁcial for selected
patients (8). As these technologies become available for
patients with either degenerative or functional MR, it will be
important for experienced referral centers and cohesive heart
teams to guide their deployment into clinical practice. As well,
the short- and long-term efﬁcacy, safety, comparative effec-
tiveness and cost of these technologies must be evaluated
through a dynamic registry supported by relevant stakeholders.
3. Critical Components for
Successful Transcatheter MR Therapies
3.1. Heart Team
The heart team approach, as utilized in the landmark
SYNTAX (TAXUS Drug-Eluting Stent versus Coronary
Artery Bypass Surgery for the Treatment of Narrowed
Arteries; NCT00114972) (9) and PARTNER (Placement of
Aortic Transcatheter Valve; NCT00530894) (1,2) trials, and
embedded in the management of patients with advanced heart
failure, is now an established paradigm for the care of patients
with complex coronary or aortic valve disease. This approach
was also followed in EVEREST (Endovascular Valve Edge-
to-Edge Repair Study), which evaluated the efﬁcacy and
safety of the MitraClip (10–12).
The key members of the heart team for transcatheter ther-
apies for MR include primary (general) cardiologists, inter-
ventional cardiologists, cardiac surgeons, imaging specialists,
valve and heart failure specialists, electrophysiologists,
cardiac anesthesiologists, catheterization laboratory technol-
ogists, perfusionists, nurses, nurse practitioners, physician
assistants, care coordinators, research coordinators, adminis-
trators, nutritionists, physical therapists, exercise physiolo-
gists, and social workers. At times, it will be appropriate to
include a geriatric cardiologist or geriatrician, particularly
when assessing frailty/comorbidities of the older adult; addi-
tional consultants may be required (nephrology, neurology, or
oncology). A heart team leader is responsible for the coordi-
nation and integration of these several contributors.
3.1.1. Role of the Primary Cardiologist
The initial diagnosis and management of the patients with MR
resides with the primary cardiologist whose clinical decision
making is informed by echocardiographic imaging, other
imaging, and exercise data as needed. He or she will determine
the timing of referral for intervention and then work with the
interventional cardiologist and cardiac surgeon to determine the
best course of action based on an individualized risk/beneﬁt
analysis and an understanding of patient values and prefer-
ences. The primary cardiologist is often in the best position to
communicate with the family throughout the care process and
will provide longitudinal follow-up after the procedure, in
coordination with the interventionalist and surgeon.
3.1.2. Role of the Imaging Specialist(s)
Accurate assessment of mitral valve anatomy and function
requires a portfolio of imaging capabilities, including 2- and
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ography and cardiac magnetic resonance imaging. Quantita-
tive assessment of the severity of mitral valve disease using
several imaging capabilities is essential before the procedure
and at follow-up. Additional insights are to be gained through
coronary angiography (either invasive or noninvasive) and
delineation of the anatomic relationship between the coronary
sinus and the mitral annulus. Standardized datasets should be
collected and the American Society of Echocardiography
deﬁnitions of severe MR (11) should be incorporated in
registry reporting. The need for other arterial or venous
imaging will be driven by the speciﬁc mitral valve technology
and its method of delivery. It is essential for the imaging
specialist to be skilled in providing live imaging capabilities
because they are often required to assist in the procedure.
3.1.3. Role of the Heart Valve and
Heart Failure Specialist
Heart valve and heart failure specialists are important
contributors to the heart team. The perspective of a heart
failure specialist is particularly appropriate for the assessment
and management of patients with MR and LV systolic
dysfunction of any etiology.
3.1.4. Role of the Interventional Cardiologist
The interventional cardiologist will be skilled in all aspects of
transcatheter structural and coronary heart disease procedures.
He or she will work collaboratively with the other members of
the heart team in the evaluation and procedural management
of the patient, as well as with early post-procedural follow-up.
Knowledge of mitral valve disease, imaging, hemodynamics,
procedure speciﬁcs, adjunct medications, and complications is
mandatory. Speciﬁc competencies will be addressed in
a forthcoming multisocietal document.
3.1.5. Role of the Cardiac Surgeon
The cardiac surgeon will see patients in collaboration with the
primary and interventional cardiologist and be competent in
catheter-based and surgical approaches to MR, including
repair and replacement options. Speciﬁc competencies will be
addressed in a forthcoming multisocietal document. It is
recognized that some surgeons have experience with and
expertise in catheter-based techniques gained through TAVR
procedures. The cardiac surgeon and interventional cardiolo-
gist will collaborate during the performance of transcatheter
mitral procedures and will designate the primary and
secondary operator as appropriate for the speciﬁc ﬁndings and
challenges encountered in any individual patient.
3.2. Specialized Facilities
3.2.1. Regional Heart Centers
Many cardiac catheterization and cardiac surgical programs
have a low volume of structural heart disease cases. In low-
volume centers, for example, mitral valve replacement may
be performedmore frequently than appropriate formanagement
of patients with degenerative MR for whom repair is stronglyrecommended. In addition, patient outcomes vary inversely as
a function of operator and institutional volume (12,13). The
National Institutes for Health and Clinical Excellence in the
United Kingdom have recommended volume criteria for mitral
valve repair (14). The challenges of evaluating and managing
patients with MR and signiﬁcant comorbidities, such as heart
failure, require multidisciplinary team care in a high-volume
referral center with the infrastructure necessary to ensure best
outcomes. The example established by the dissemination of
TAVR should pertain to the release of therapies for MR.
Accordingly, a detailed list of facilities and personnel experi-
ence, pre- and post-procedural care protocols, and complication
management strategies must be developed and maintained. All
data must be standardized and sent to a central registry for
analysis and reporting. The level of commitment needed at the
institutional level to establish and maintain the program cannot
be overstated.
3.2.2. Procedure Setting
A cardiac catheterization laboratory with adequate space
(w800 sq ft) to accommodate the operators, imagers, cardiac
anesthesiologists, support staff, and their necessary equipment
(including transesophageal echocardiography equipment,
anesthesia machines, and intra-aortic balloon pumps) is
mandatory. There must be high-quality, single-plane ﬂuoros-
copy and cineangiography. Other imaging modalities, such as
computed tomography and magnetic resonance imaging with
real-time 3-dimensional reconstruction, are expected to play an
increasing role during the procedure. A hybrid operating suite is
not strictly necessary for mitral procedures at this stage of
development, but laminar air ﬂow to provide operating room–
level sterility is mandatory. Should a transcatheter mitral valve
replacement option evolve, however, a hybrid suite with the
capability for cardiopulmonary bypass would be needed. The
equipment necessary to perform the procedure, includingwires,
sheaths, balloons, and devices of multiple sizes must be avail-
able. Support staff may include individuals with a predominant
background and skill set in either interventional or surgical
procedures, as dictated by patient- and procedural-speciﬁc
needs. Procedural teams function best with both disciplines
represented and working collaboratively.
It is anticipated that patients will be cared for in specialized
cardiac or cardiac surgical intensive care units after the proce-
dure, then transitioned to telemetry care as their hemodynamics,
rhythm, respiratory status, and vascular access issues allow. It
will be important for institutions to designate a single intensive
care area for post-procedural care to optimize expertise, team
training, and the development of care protocols. Expertise may
require integration of cardiac and surgical nursing competencies.
4. Literature Review
4.1. Clinical Trials in the United States
Approaches under investigation for transcatheter mitral valve
repair or replacement include the edge-to-edge clip, off-pump
adjustable neochordal implantation, indirect annuloplasty
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844(generally via coronary sinus remodeling), cinching devices to
induce annular reduction, external compression, direct
annuloplasty (transcatheter surgical rings or sutures), energy-
mediated annuloplasty (collagen shrinking), and transcatheter
mitral valve replacement. Of the above technologies, the
edge-to-edge MitraClip has undergone the most extensive
human investigation thus far (15). This device is fashioned
after a direct surgical method that relies on suture approxi-
mation of the leaﬂets to create a double oriﬁce valve (16).
The initial U.S. experience with transcatheter mitral valve
repair for MR in 27 patients using the MitraClip was reported
in the EVEREST phase I trial in 2005 (17), with a subsequent
expanded analysis in 2009 of 107 patients with at least 1-year
follow-up (10). This initial experience was favorable in terms
of acute procedural success, safety, and functional outcome,
although 30% of patients required mitral valve surgery for
treatment of 3 or 4þ MR within 3.2 years of device
implantation.
The pivotal EVEREST II trial (NCT00209274) randomized
279 patients with 3 or 4þ chronic MR secondary to mal-
coaptation of the middle scallop of the anterior and posterior
leaﬂets in a 2:1 ratio to transcatheter MitraClip repair versus
open surgical repair (18). The primary efﬁcacy endpoint at 12
months (composite of freedom from death, surgery for mitral
valve dysfunction, and 3 or 4þ MR) was reached in 57% of
transcatheter MitraClip repair patients versus 73% of surgical
patients (p ¼ 0.007). Mortality rates were similar between
groups and the efﬁcacy outcome difference was driven by
a 20% incidence rate of surgery for mitral valve dysfunction
in the MitraClip arm (versus 2% in the surgery arm, p <
0.001). Although the rate of 3 or 4þ MR at 12 months was
nearly identical for the groups (21% transcatheter repair
versus 20% surgery), in this intention-to-treat analysis,
patients assigned to surgery, but who did not undergo surgery,
were considered treatment failures. In a per-protocol analysis,
freedom from death, mitral valve surgery for persistent MR,
and the occurrence of 3 to 4þ MR at 12 months was 72% for
the transcatheter arm compared with 88% for surgery (p ¼
0.02). The incidence rates for 3 to 4þ MR at 1 year in this
per-protocol analysis were 17% in the transcatheter therapy
arm versus 4% in the surgery arm (p ¼ 0.01). The primary
safety outcome, a composite of major adverse events at 30
days, favored the transcatheter group (15% transcatheter
repair arm versus 48% surgery arm; p < 0.001). The higher
rate of major adverse events in the surgery arm at 30 days was
driven largely by an excess hazard of transfusion of 2 or more
units of blood (13% transcatheter repair arm versus 45%
surgery arm; p < 0.01). With open surgery, the incidence of
major morbidity, as deﬁned by the STS, was 9% versus 2% in
the transcatheter arm (p ¼ 0.02). At 4 years, overall mortality
was similar between groups (17% transcatheter arm versus
18% surgery; p ¼ 0.91) with mitral valve surgery or reoper-
ation more often necessary following transcatheter repair
(25% transcatheter arm versus 5% surgery arm, p < 0.001)
(19). Following transcatheter repair at 4 years, MR grade was
0 to 1þ in 42% of patients, 2þ in 37%, and 3 to 4þ in 21%.Following surgical repair at 4 years, MR grade was 0 to 1þ in
82%, 2þ in 9%, and 3 to 4þ in 9% (p < 0.001).
Seventy-eight patients with 3 or 4þ symptomatic MR for
whom the predicted perioperative mortality rate was 12%
were enrolled in the EVEREST II High Risk Study (HRS)
(20). Fifty-six percent of patients had functional MR, and
44% of patients had degenerative MR. A referent group of
patients who were screened concurrently, but not enrolled,
allowed for survival comparison with a group managed
conservatively. In the treated group, the MitraClip reduced the
severity of MR in a majority of patients and was associated
with improved symptoms, LV reverse remodeling, recurrent
heart failure hospitalizations, quality of life, and survival at 12
months (20). Implantation of the MitraClip was successful in
95% of 127 prohibitive-surgical-risk patients with degenera-
tive MR treated between 2003 and 2012 (21). One-year
survival was 74% and was associated with similar improve-
ments in functional status, quality of life, indices of LV
remodeling, and recurrent hospitalizations for heart failure in
this anatomic cohort.
Salutary effects included reduced MR grade, LV reverse
remodeling, fewer rehospitalizations for heart failure, and
improved quality of life. The COAPT (Clinical Outcomes
Assessment of the MitraClip Percutaneous Therapy for High
Surgical Risk Patients; NCT01626079) and RESHAPE-HF
(Randomized Study of the MitraClip Device in Heart
Failure Patients With Clinically Signiﬁcant Functional Mitral
Regurgitation; NCT01772108) trials have been designed to
evaluate the MitraClip therapy in very high surgical risk
patients with functional MR, reduced LV ejection fraction,
and New York Heart Association functional class III or IV
heart failure.
4.2. European Registry and
Observational Studies
The MitraClip system received CE Mark approval in March
2008 and commercialization began in September 2008. The
ACCESS-EU (ACCESS-Europe A Two Phase Observational
Study of the MitraClip System in Europe) phase I study began
enrolling patients in Europe in April 2009. Enrollment in
ACCESS-EU phase I was completed on April 13, 2011, and
12-month clinical data collected as of June 15, 2012, were
reported in September 2013 (22). The implant success rate was
99.6% for 567 patients (EuroSCORE [European System for
Cardiac Operative Risk Evaluation] 23  18%) enrolled from
14 centers. Thirty-day and 1-year mortality rates were 3.4%
and 19%, respectively. By 1 year, open mitral valve surgery
was necessary in 6.3% of patients, 3.4% of patients required
a second MitraClip procedure to treat residual MR, and the
incidence of 3 to 4þ MR was 21%. Among the 1-year
survivors, 71% were in New York Heart Association func-
tional class I or II with improvements in 6-min walk test and
quality of life scores. With functional valve disease, MR grade
at 1 year was 3 to 4þ in 21%, 2þ in 47%, and 0 to 1þ in 32%
of patients. With degenerative valve disease, MR grade at 1
year was 3 to 4þ in 25%, 2þ in 42%, and 0 to 1þ in 33% of
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845patients. In this post-approval European experience, MitraClip
therapy was most frequently applied to high-risk, elderly
patients, mainly with functional MR. Several other European
observational studies in patients with both degenerative and
functional MR, including high-surgical-risk patients, have
been reported with directionally similar results (23–28).
Investigators have cautioned that pre-assessment, treatment,
and post-procedural care by an interdisciplinary team are
essential to maximize clinical success, especially in high-
surgical-risk patients. The 2012 European Society of Cardi-
ology Guidelines on the Management of Valvular Heart
Disease state that MitraClip may be considered for patients
with life expectancy >1 year and symptomatic severe,
secondary (functional) MR despite optimal medical therapy
(including cardiac resynchronization therapy when indicated)
who are deemed high risk or inoperable by a formal heart team
(Class IIb, Level of Evidence: C) (6). Surgical repair after
failed MitraClip deployment is feasible, although more
extensive valve scarring after clip implantation may necessitate
valve replacement (29). Thirty-seven of 178 MitraClip patients
in EVEREST II underwent open mitral valve surgery within
12 months of implant. Valve repair was possible in 20 patients,
and valve replacement was required in 17 patients. Removal of
the MitraClip was more difﬁcult after 30 days because of
ﬁbrosis and scarring of the leaﬂets. Anterior leaﬂet pathology
was a predictor of the need for valve replacement (30).
4.3. Other Transcatheter
Mitral Valve Technologies
Transcathetermitral annuloplasty via the coronary sinushas been
assessed in the CARILLON AMADEUS (Mitral Annuloplasty
Device European Union) (31) and TITAN (Transcatheter
Implantation of Carillon Mitral Annulplasty Device) (32) trials
using the CARILLON Mitral Contour System (Cardiac
Dimensions, Kirkland, Washington), and in studies using an
alternative device (PTOLEMY [Safety and Efﬁcacy of the
Percutaneous Transvenous Mitral Annuloplasty (PTMA)
Device]; NCT00568230) (33). Recruitment in a subsequent
evaluation of the PTMA device (PTOLEMY2Canada [Safety
and Efﬁcacy Study of the PTMADevice to ReduceMitral Valve
Regurgitation in Patients With Heart Failure]; NCT00815386)
(34) was suspended once the device manufacturer ceased oper-
ations in 2011. Technical and anatomic challenges have thus far
impeded application of coronary sinus annuloplasty devices
although a potential adjunct role for their use in selected patients
may emerge. Transapical beating heart mitral valve repair with
deployment of neochordae has been reported (35). Human
experiencewith other transcatheter devices, such as a septal sinus
shortening system, has been extremely limited to date (36).
5. Operator Training
It is incumbent on professional societies to set minimal
performance standards for these procedures rather than to
defer to commercial sponsors. The societies should developthe curriculum, establish the metrics for evaluation, and
certify completion of a training module. Challenges to this
paradigm include access to a required minimum of cases, the
appropriate balance of simulation and/or large animal labo-
ratory experience, the limited number of centers at which
these procedures have been performed to date, the limited
number of senior mentors, and the disadvantages faced by
operators and surgeons who have graduated from training
programs and are now in practice. Our societies have outlined
the speciﬁcs of a training curriculum in interventional
fellowships for structural and adult congenital heart disease
(37). Unanswered questions concern the duration of training,
funding, team-based training needs, and the expectations for
interventionalists and surgeons. The establishment of such
training criteria, procedural volumes, and performance and
evaluation metrics are beyond the scope of the document and
will be addressed in the forthcoming SCAI/AATS/ACC/STS
Multisocietal Consensus Statement: Operator and Institutional
Requirements for Transcatheter Valve Repair and Replace-
ment: Part 3: Mitral Valve (38).
6. Protocols for Care
Speciﬁc protocols for pre-, intra-, and post-procedural
patient assessment and care should be in place with clear
delineation of the roles of the individual heart team members
and establishment of a collaborative process for shared
decision making with the patient. Protocols should involve
assessment of mitral valve anatomy and function, cardiac
chamber sizes, biventricular function, pulmonary artery
pressures, and any concomitant aortic or tricuspid valve
pathology. Knowledge of the coronary anatomy will be
required. A complete assessment of medical comorbidities is
a key component of this process. The need for other proce-
dures (such as coronary revascularization) that may be
indicated to achieve an optimal result should be identiﬁed.
All patients referred for consideration of transcatheter
therapy for MR should proceed down the same evaluation
and treatment pathway so as to promote consistency, reduce
variability, and allow for more uniform reporting of results.
The process should help prevent inappropriate use of the
technology, as well as post hoc misinterpretation of the data
needed for optimal device utilization. Provision of longer-
term follow-up care must be speciﬁed and protocols for
surveillance imaging established.
7. Assessment of Outcomes
Clinical, procedural, device, and administrative data collec-
tion, analysis, and reporting are vital aspects of the process
whereby the utility and safety of any new technology can be
established. The value of robust patient registries has been
demonstrated most convincingly by the STS National Data-
base and the ACC National Cardiovascular Data Registry
(NCDR). In the ASCERT (ACCF/STS Collaboration on the
O’Gara et al. JACC Vol. 63, No. 8, 2014
Transcatheter Therapies for Mitral Regurgitation Societal Overview March 4, 2014:840–52
846Effectiveness of Revascularization Strategies) study, these 2
databases were conjoined and then linked to the Social
Security Death Master File and the Centers for Medicare &
Medicaid Services (CMS) Medicare Provider and Analysis
Review repositories to inform outcomes analysis and
comparative effectiveness research on real-world patients
undergoing coronary revascularization (39). A novel, national
clinical registry program for new transcatheter valve therapy
(TVT) devices was created in December 2011 following Food
and Drug Administration (FDA) approval of the Sapien
Transcatheter Aortic Valve (40). The TVT registry
(NCT01737528), a joint initiative of the STS and ACC, was
developed in close collaboration with the FDA, CMS, and the
Duke Clinical Research Institute (41). Its purpose is to
provide an objective, comprehensive, and scientiﬁcally based
resource to improve the quality of patient care, monitor the
safety and effectiveness of novel transcatheter valve tech-
nologies, serve as a platform for TVT research, and enhance
communication among multiple stakeholders. It is linked to
other national and international registries to facilitate its
mission. Importantly, the TVT registry fulﬁlls the CMS
National Coverage Determination (NCD) (May 2012)
requirement for national registry participation for all TAVR
centers. The registry enables device and procedure surveil-
lance, quality improvement, and the performance of device
labeling studies to speed access to new devices and support
expansion of labeling with evidence development. The ﬁrst
TVT registry–embedded post-approval study was developed
in partnership with the FDA and Edwards Lifesciences, the
industry sponsor of the ﬁrst FDA-approved transcatheter
aortic valve. Several more are now under discussion and in
early development. The ﬁrst embedded investigational new
device study undertaken through the registry and sponsored
by STS and ACC, with the approval of FDA and CMS, led in
a short time to expanded indications for TAVR (42). The
addition of transcatheter MR therapies and other heart valve
lesions is a logical and necessary extension of the TVT
registry. The process to incorporate mitral technologies has
already begun, with careful delineation of the critical data
elements that must be captured in a standardized and well-
deﬁned manner with seamless linkage to other databases
and harmonization with pivotal clinical trials to inform
regulatory approval, promote best practices, and ensure high-
quality patient-centered care. It is anticipated that partici-
pating centers will collect information regarding patient
demographics, comorbidities, functional status, patient-
reported quality of life, hemodynamics, procedural details,
and post-procedure 30-day and 1-year outcomes.8. Summary and Recommendations
Transcatheter therapies hold promise for the management of
carefully selected patients with severe MR using less invasive
means whereby the experience of care may be improved.
Although registry experience in the United States and Europehas been encouraging, only a single randomized trial using
a speciﬁc device in patients with MR has been reported with
recent FDA approval for use of this device in eligible U.S.
patients with degenerative MR. Further research involving
awider spectrum of patients and devices is strongly encouraged.
It is recognized that the intricate structure and complex function
of the mitral apparatus pose challenging technical hurdles. It is
imperative that professional societies, industry, payers, and
regulatory agencies work collaboratively to promote needed
research and ensure that the technology is disseminated ratio-
nally and responsibly in the best interests of patients. The
following recommendations for a path forward closely mirror
those enunciated in a previous ACCF/STS Societal Overview
(3). The leadership of our organizations proposes:
1. Continued development of regional heart valve referral
centers of excellence. Criteria for the performance of
transcatheter therapy for MR in such centers should be
established and reﬁned. Availability of new devices and
reimbursement for their application should be limited to
those centers that meet national criteria.
2. A heart valve referral center of excellence is deﬁned in
part by the competence and experience of the indi-
vidual members of a dedicated, multidisciplinary heart
team, each of whom has a clearly deﬁned role and
works collaboratively in the best interest of patients.
Input is required from general cardiologists, heart valve
and heart failure experts, advanced imagers, inter-
ventionalists, cardiac surgeons, and allied members of
the heart team (e.g., anesthesia, geriatrics, neurology,
nephrology, nursing, care coordination, pharmacy,
physical therapy, and social work). All aspects of
patient evaluation and care must be addressed,
including late follow-up. Lack of dedicated care path-
ways should disqualify a center from participation.
3. All centers are required to participate in an ongoing
TVT registry to benchmark quality and enable
outcomes and cost analysis, as well as comparative
effectiveness research. Data quality, as well as
productivity in publication of research projects from the
registry, should be monitored.
4. Operator training and credentialing criteria for mitral
valve procedures must be established and are the
subject of a joint professional competency document in
development.
5. Guidelines for transcatheter mitral valve interventions
should be substantiated and developed. Performance
measures and appropriate use criteria would follow.
Presently, the MitraClip is approved only for prohibitive
surgical risk patients with degenerative MR who meet
anatomic eligibility criteria. The COAPT trial
(NCT01626079) will address the role of the MitraClip
device in high surgical risk patients with functional MR.
The ACC, AATS, SCAI, and STS are committed to the
principle of working collaboratively together as professional
societies and in partnership with the FDA, CMS, and industry
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847partners to bring promising, innovative mitral valve technol-
ogies into clinical practice as validated by the evidence and in
the best interests of patients.
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